Antidepressant and Antipsychotic to Treat Attenuated Positive and Negative Symptoms

• Status: Completed
• Trial end date: 2007-04-01
• Target enrollment: 0
• Participant gender: All

Summary

The Recognition and Prevention (RAP) Program is conducting a research study comparing an antidepressant, sertraline, alone versus in combination with a second-generation antipsychotic, risperidone, to evaluate their ability to reduce unusual thoughts, suspiciousness and other unusual experiences, to improve reasoning ability, memory, attention and social skills in adolescents.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Northwell Health
• Collaborators: Janssen Pharmaceutica N.V., Belgium; Pfizer; Stanley Medical Research Institute
• Treatments: Risperidone; Sertraline

Criteria

Inclusion Criteria:

• Participants are between the ages of 12 and 22.

• Participants are English-speaking.

• Participants are experiencing one or more symptoms like unusual thoughts, suspiciousness, or unusual perceptual experiences.

• Participants meet additional RAP criteria (evaluated during screening and interview).

Exclusion Criteria:

• Participants have been diagnosed with an Axis I psychotic disorder, including:

schizophreniform disorder, schizophrenia, schizoaffective disorder, bipolar disorder, or major depression with psychotic features.

• Participants have a history of neurological, neuroendocrine, or other medical conditions known to affect the brain.

• Participants have a medical condition that contraindicates treatment with sertraline or risperidone.

• Participants have past or current substance dependence.

• Participants are currently taking and responding well to antidepressant or antipsychotic medication